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This study aimed to estimate the prevalence of infection by the hepatitis B virus (HBV)
and hepatitis C virus (HCV) in people infected by the human immunodeﬁciency virus (HIV)
and  analyze sociodemographic and behavioral factors associated with such co-infection. A
cross-section study was performed in 495 individuals treated at a public center in the city
of  Goiânia. Participants were interviewed and blood collected for evaluation of serological
and molecular markers for HBV and HCV. The rate of exposure to HBV was 33.5% (95% CI
29.4–37.9). Nineteen patients (3.8%) were diagnosed as HBV carriers, of whom 68.4% were
HBV DNA positive. The prevalence of anti-HCV was 9.7% (95% CI 7.3–12.7). Genotype 1a was
identiﬁed in 72.7% of the PCR samples positive for HCV. Co-infection by all three viruses was
4.4%  (95% CI 2.9–6.8). Being, male, aged ≥40 years, history of sexually transmitted disease
(STD), and having homosexual practices were independently associated with the presence
of  markers of HBV exposure. A history of injectable drugs use and STDs showed association
with HCV seropositivity. Approximately 50% of participants were not aware of their HBV andHCV serostatus. The results obtained may contribute to assess the burden of viral hepatitis
in  people living with HIV and to guiding preventive measures for more  vulnerable groups.
© 2015 Elsevier Editora Ltda. All rights reserved.
of HIV patients recommend testing for infection markersIntroduction
Hepatitis B (HBV) and C (HCV) viruses are responsible for
the most common chronic viral infections worldwide. The
prevalence of HBV and HCV infection is higher among peo-
ple living with the human immunodeﬁciency virus (HIV)
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1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.compared to the general population due to the common trans-
mission routes and the overlap of behavioral risk factors
for these viruses.1 Guidelines for the clinical managementa da Universidade Federal de Goiás Rua 235, s/n, IPTSP/UFG, Setor
for viral hepatitis, and clinical evidence shows that co-
infections are associated with worse prognosis of the liver
disease.2,3
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type 1b) and 13.6% for genotype 3. Of the 22 individuals with
detectable viral load for HCV, four did not know they were
infected, and of the 18 who knew, 11 reported being treated
Table 1 – Prevalence of serological markers of exposure
to hepatitis B and C viruses in 495 HIV-infected
individuals treated in a public health center of Goiânia –
Goiás.
Markers of exposure n (%) (95% CI)
Hepatitis B
Anti-HBc+ and/or HBsAg+ 166 (33.5) (29.4–37.9)
HBsAg+ 19 (3.8) (2.4–6.0)
Anti-HBc+ (isolated) 40 (8.1) (5.9–10.9)
Anti-HBc+ and anti-HBs+ 107 (21.6) (18.1–25.6)
Hepatitis C
Anti-HCV 48 (9.7) (7.3–12.7)
ab r a z j i n f e c t d i s .
The investigation of the presence of HBV and HCV in HIV
nfected patients is important from the public health per-
pective to measure the resources required for prevention
nd treatment. Currently, HIV infected patients have greater
ongevity due to effective antiretroviral regimens as well as
ore  effective drugs to treat hepatitis B and C. Thus, estimat-
ng the magnitude of co-infection in different populations is
elevant.
The prevalence of HIV-HBV or HIV-HCV co-infection
resents great variation and reﬂects differences in the
ociodemographic proﬁle, lifestyle, and hepatitis B immu-
ization coverage in different population groups. A recent
ystematic review of the national literature showed that the
revalence of HCV infection among HIV infected individu-
ls ranges from 3.3 to 82.4%.4 It is worth noting that most
stimates of prevalence of HIV and hepatitis B and C co-
nfections were obtained in the South and Southeast regions of
razil. This study aimed to estimate the prevalence of HBV and
CV infection among HIV-infected individuals and to investi-
ate factors associated with co-infection in the state of Goiás.
hese results may contribute to assessing the burden of viral
epatitis in people living with HIV and to guiding preventive
easures for more  vulnerable groups.
ethods
his cross-sectional study included HIV-infected patients,
ged 18 years or more,  treated at public health services in the
ity of Goiânia, state of Goiás, Brazil. The participants were
ecruited sequentially from March to May 2011 until achieving
he necessary sample size. A sample of 450 patients was con-
idered to be sufﬁcient to detect prevalence of 2,0% for HBV
anti-HBc) and HCV (anti-HCV) infection, with 1% precision
nd a 95% conﬁdence interval (95% CI).
After signing the informed consent form, participants
nderwent a structured interview to investigate sociodemo-
raphic, clinic and behavioral variables potentially associated
ith co-infection. Blood was collected to perform laboratory
ests. Enzyme immunoassays were performed (3rd genera-
ion ELISA) to search for serological markers of hepatitis B
total anti-HBc, HBsAg, anti-HBs) and hepatitis C (anti-HCV).
BV DNA was assayed (PCR – Real Time) in all HBsAg-positive
amples. HCV viral load was quantiﬁed (PCR – Real Time) in
ll anti-HCV-positive samples. We  considered the presence of
CV RNA as a marker of infection activity. HCV genotyping
nd subtyping (PCR – Real Time) were performed for all samples
hat showed detectable HCV RNA. The history of antiretroviral
rug use was obtained from the records of distribution centers
f these drugs. CD4 T lymphocytes and HIV-1 viral load quan-
iﬁcation values were obtained from the records of the Central
aboratory (Laboratório Central – LACEN) – Goiás.
The prevalence of HBV and/or HCV infection, with their
espective 95% CI, were estimated. A univariate analysis was
erformed to evaluate the relationship between outcome
ariables (positive for HBV or HCV) and different exposure
ariables (sociodemographic and behavioral variables). The
dds Ratios (ORs) and their respective 95% CI were calculated.
he variables that reached a signiﬁcance level lower than 0.10
or association with HBV or HCV positivity in the univariate5;1 9(4):426–430 427
analysis were included in the logistic regression model, and
the adjusted OR was calculated. In the multivariate analysis,
a signiﬁcance level lower than 0.05 was established. The statis-
tical software SPSS 15.0 was used. The project was approved by
the Ethics and Research Committee of the Pontiﬁcal Catholic
University of Goiás.
Results
This study included 495 individuals, of which 366 were male
(73.9%). The age of the participants ranged from 18 to 70
years (median age of 40 and interquartile range from 32 to 47
years). Previous use of injectable drugs was reported by 4.6%
of men  and 0.8% of women (p < 0.05). Sexual intercourse with
drug users was reported by 5.2% of men  and 14.5% of women
(p < 0.01). History of blood transfusion and tattoos was reported
by 13.9% and 18.8% of individuals, respectively, with no differ-
ences between men  and women. Approximately half of the
participants (n = 221) reported at least one episode of sexually
transmitted disease, most frequently gonorrhea (n = 95) and
syphilis (n = 83). The median period since HIV diagnosis was six
years with an interquartile range from two to 10 years. The use
of antiretroviral therapy was reported by 74.9% of participants.
The prevalences of hepatitis B and C are presented in
Table 1. The presence of at least one marker of exposure to
the hepatitis B virus (anti-HBc and/or HBsAg) was detected
in 166 participants, resulting in a prevalence of 33.5% (95%
CI 29.4–37.9). Nineteen patients (3.8%; 95% CI 2.4–6.0) were
HBsAg-positive, of whom 13 (68.4%) were positive for HBV
DNA detection. Among the 19 HBsAg-positive individuals, 10
(52.6%) were not aware of their HBV infection. The prevalence
of HCV infection was 9.7% (95% CI 7.3–12.7), and 54.2% of HCV
ELISA positive individuals were not aware of their serostatus.
For quantitative HCV RNA, of the 48 anti-HCV-positive indi-
viduals, 22 (45.8%) had a detectable viral load, ranging from
598 to 6,288,232 copies/mL. The frequency of HCV genotypes
was 86.4% for genotype 1 (72.7% of subtype 1a and 9.1% of sub-Hepatitis B and C 22 (4.4) (2.9–6.8)
n, number of cases; 95% CI, 95% conﬁdence interval; +, positive.
a Hepatitis B and C = anti-HBc+ and/or HBsAg+ and anti-HCV+.
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Table 2 – Univariate analysis of factors associated with exposure to hepatitis B (HBV) and C (HCV) viruses in 495
HIV-infected individuals treated in a public health center in Goiânia – Goiás.
Risk factors Exposure to HBVa OR (95% CI) p Exposure to HCVb OR (95% CI) p
Yes No Yes No
Gender
Male 149 217 4.5 (2.6–7.8) <0.01* 35 331 0.9 (0.5–1.8) 0.87
Female 17 112 13 116
Age
≥40 years 102 157 1.7 (1.2–2.6) <0.01* 26 233 1.1 (0.6–2.0) 0.79
<40 years 64 172 22 214
Education
<9 years 53 130 0.7 (0.5–1.1) 0.10* 22 161 1.5 (0.8–2.7) 0.18
≥9 years 113 199 26 286
Presence of tatoo
Yes 28 65 0.8 (0.5–1.3) 0.44 12 81 1.5 (0.8–3.0) 0.25
No 138 264 36 366
History of blood transfusionc
Yes 24 45 1.1 (0.6–1.8) 0.84 9 60 1.5 (0.7–3.2) 0.32
No 142 281 39 384
History of STDd
Yes 100 121 2.6 (1.8–3.8) <0.01* 34 187 3.4 (1.8–6.4) <0.01*
No 66 207 14 259
IDU
Yes 6 12 1.0 (0.4–2.7) 0.99 10 8 14.4 (5.4–38.7) <0.01*
No 160 317 38 439
Sex with IDUe
Yes 8 29 0.5 (0.2–1.1) 0.09* 7 30 2.3 (1.0–5.6) 0.06*
No 158 291 41 408
Sexual orientation
Homo/bisexual 95 91 3.5 (2.4–5.2) <0.01* 14 172 0.7 (0.3–1.3) 0.21
Heterosexual 71 238 34 275
Time of HIV diagnosisf
≥6 years 86 163 1.1 (0.7–1.6) 0.66 29 220 1.6 (0.9–2.9) 0.14
<6 years 80 165 19 226
Exposure to HCVb
Yes 22 26 1.8 (1.0–3.2) 0.06* – – – –
No 144 303 – –
OR, odds ratio; 95% CI, 95% conﬁdence interval; p, signiﬁcance (<0.10).
∗ Signiﬁcant; STD, sexually transmitted diseases; IDU, injectable drug users.
a Exposure to HBV = anti-HBc+ and/or HBsAg+.
b Exposure to HCV = anti-HCV+.
c 3 individuals reported not knowing their blood transfusion history.
ith ad 1 individual reported not knowing if he had a history of STD.
e 9 individuals reported not knowing if they had sexual intercourse w
f 1 individual reported not knowing the time of HIV diagnosis.
for hepatitis C. Twenty-two participants showed markers of
exposure to hepatitis B and C viruses, which resulted in a
prevalence of co-infection of 4.4% (95% CI 2.9–6.8).
Table 2 presents the results of the univariate analysis for
factors potentially associated with markers of exposure to
HBV (HBsAg and/or total reactive anti-HBc) or HCV (anti-
HCV). After multivariate analysis, male individuals (adjusted
OR = 2.0; 95% CI 1.1–3.8), age equal to or higher than 40 years
(adjusted OR = 2.4; 95% CI 1.5–3.8), reported history of sex-
ually transmitted diseases (STDs) (adjusted OR = 1.9; 95% CI
1.2–2.9), and homosexuality or bisexuality (adjusted OR = 3.7;
95% CI 2.2–6.3) were independently associated with a signiﬁ-
cantly higher risk of having markers of HBV infection. Patientsny IDU.
with a history of STDs had almost three times higher risk of
being anti-HCV positive (OR = 2.7; 95% CI 1.4–5.4) compared
with patients who denied having STDs. A history of injectable
drugs use was associated with almost 12-fold the risk of HCV
infection (anti-HCV positive) compared with individuals who
did not use drugs (OR = 11.8; 95% CI 3.9–35.8).
DiscussionThe prevalence of co-infection with the hepatitis B and C
viruses was estimated in a population of adults with a pre-
dominance of males whose exposure route to HIV was mostly
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immunodeﬁciency virus/hepatitis C virus co-infection in
Brazil and associated factors: a review. Braz J Infect Dis.
2013;17:455–63.
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exual. The prevalence of HBV carriers (HBsAg) was 3.8% and
f anti-HCV was 9.7%. These prevalences are six to seven
old higher than the rates found in a population-based study
onducted in capital cities of the Midwest.5,6 These results
ndicate a high potential morbidity burden in the coming years
ue to co-infection with HIV and viral hepatitis.
In Brazil, studies conducted with HIV-infected individuals
ave found prevalences of HBsAg or anti-HBc carriers rang-
ng, respectively, from 3.7 to 27.3% or from 38.6 to 55.1%.7–10
hese differences probably reﬂect the percentage of risk fac-
ors in the studied groups and the endemicity pattern for HBV
n different regions. In this study, 3.8% (95% CI 2.4–6.0) of par-
icipants were carriers of the hepatitis B virus, and HBV DNA
as detected in approximately 65% of HBsAg-positive cases.
ince hidden HBV infection was not investigated in this study,
his may have underestimated the prevalence of HBV-infected
ndividuals.11 Moreover, a negative result of the molecular
est does not rule out the presence of the virus because
iremia may be undetectable or temporarily suppressed due
o antiretroviral drugs. The Brazilian Immunization Program
ecommends that HIV-infected individuals should be inves-
igated for HBV infection and the susceptible ones should be
accinated. The present study was not designed to assess vac-
ine coverage or lost opportunities for immunization against
BV, thereby, anti-HBs was investigated only in anti-HBc pos-
tive patients.
Regarding the factors associated with HBV infection in peo-
le living with HIV, the results of this study are consistent
ith the national and international literature, in which higher
revalence of HBV were described in older male individuals
ith homosexual practices. The association between older age
roups and HBV is a well-known and widely observed fact
esulting from the increased risk of exposure with time and
he greater vaccination coverage in younger populations.1,12
Less than 5% of participants reported a history of injectable
rugs use, and the prevalence of HCV was 9.7%. Conversely,
n studies conducted in the South and Southeast regions of
razil, from 20 to 100% of participants were injectable drug
sers (IDUs), and the percentage of individuals co-infected
ith HCV reached 80%.9,13 Although the percentage of IDUs
n this sample is small when compared with these studies,
he use of injectable drugs still exhibited a strong association
ith HCV-positivity, which is consistent with the literature.
lso, the association between HCV and the history of STDs
as supported by the study, which indicates the impor-
ance of the sexual transmission of HCV through unprotected
ex.14,15
HCV RNA was detected in approximately half of anti-HCV-
ositive samples. We  assume that the absence of HCV RNA is
ndicative of previous infection with elimination of the virus
permanent or temporary) or represents a false-positive result
f the serological test used for triage, although all anti-HCV-
ositive samples had been tested in duplicates. Similar results
ere described with percentages close to 50% detection of
CV RNA in anti-HCV-positive samples in other studies in
razil.16,17 In contrast, HCV RNA was detected in approxi-
ately 90% of HIV-positive individuals who had never been
13reated for HCV in the South region. The variations in the
roportion of HCV RNA detection in anti-HCV samples in
ifferent studies probably reﬂect methodological differences,5;1 9(4):426–430 429
which include the degree of exposure to antiretroviral drugs
in different population groups.
Regarding the genotypic proﬁle of HCV, we  identiﬁed a
predominance of genotype 1, followed by genotype 3. The pre-
dominance of genotype 1 is consistent with results obtained
in various studies conducted in Brazil.13,16,18,19 Genotype 1 has
a worse therapeutic response than genotypes 2 and 3.2,3 Geno-
type 3 and subtype 1a have been associated with transmission
in IDUs.16,17,20 The presence of genotype 3 in the popula-
tion studied could indicate the importance of injectable drugs
for HCV transmission in HIV-infected patients. However, the
study was not designed to analyze the association between
genotypes and the HCV transmission route.
It is noteworthy that 50% of patients with positive serol-
ogy for HBsAg or anti-HCV reported not knowing they
were infected. These results do not allow us to state that
these patients had not been previously examined or coun-
seled regarding these infections because they were all being
followed-up in specialized reference centers. This population
might require a differentiated approach to minimize loss of
opportunities for treatment and transmission reduction.
Some limitations of this study are inherent to cross-
sectional studies, making it difﬁcult to establish a temporal
relationship between co-infections and potential exposure
variables. Although the sample was not random, individuals
were recruited in the main specialized diagnosis public cen-
ter, where almost all HIV-infected patients of the municipality
undergo periodic tests to monitor the HIV viral load and CD4
count.
Despite the methodological limitations mentioned, this
study allowed for prevalence estimation and delineation of
the proﬁle of HIV-infected patients co-infected with the hep-
atitis B and C viruses treated in public centers of Goiás. The
results obtained indicate the need for future studies that allow
reducing the clinical and economic impact of long-term co-
infections in this population.
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